You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
How Circulating Tumor Cells Escape From Multidrug Resistance
|
|---|---|
| Published in |
American Journal of Clinical Oncology: Cancer Clinical Trials, December 2011
|
| DOI | 10.1097/coc.0b013e3181f94596 |
| Pubmed ID | |
| Authors |
Angela Gradilone, Cristina Raimondi, Giuseppe Naso, Ida Silvestri, Lazzaro Repetto, Antonella Palazzo, Walter Gianni, Luigi Frati, Enrico Cortesi, Paola Gazzaniga |
| Abstract |
Resistance to anthracyclines is responsible for treatment failure in most patients with metastatic breast cancer. According to recent studies, the expression of specific drug transporters (MRPs) on circulating tumor cells is predictive of prognosis in different cancer types. We observed that patients whose circulating tumor cells expressed MRP1 and MRP2, two drug-export pumps responsible for anthracyclines efflux, who received conventional anthracyclines had a significantly shorter time to progression compared with patients sharing same characteristics who received non pegylated liposomal doxorubicin (P < 0.005). These results may highlight a new appealing role of the liposomal doxorubicin formulation, not only because of its reduced cardiac toxicity but especially referring to its theoretical efficacy in anthracycline-resistant breast cancer patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 4% |
| United States | 1 | 4% |
| Unknown | 25 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 15% |
| Other | 4 | 15% |
| Student > Ph. D. Student | 4 | 15% |
| Student > Doctoral Student | 3 | 11% |
| Student > Postgraduate | 2 | 7% |
| Other | 4 | 15% |
| Unknown | 6 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 33% |
| Agricultural and Biological Sciences | 4 | 15% |
| Biochemistry, Genetics and Molecular Biology | 3 | 11% |
| Chemistry | 2 | 7% |
| Sports and Recreations | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 6 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 November 2011.
All research outputs
#20,955,550
of 25,738,558 outputs
Outputs from American Journal of Clinical Oncology: Cancer Clinical Trials
#1,054
of 1,758 outputs
Outputs of similar age
#205,752
of 247,967 outputs
Outputs of similar age from American Journal of Clinical Oncology: Cancer Clinical Trials
#4
of 14 outputs
Altmetric has tracked 25,738,558 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,758 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,967 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.